Exelixis
EXEL
#1855
Rank
C$15.15 B
Marketcap
C$56.30
Share price
-2.18%
Change (1 day)
17.97%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2025 (TTM): C$3.30

According to Exelixis's latest financial reports the company's current EPS (TTM) is C$3.24. In 2023 the company made an earnings per share (EPS) of C$0.89 an increase over its 2022 EPS that were of C$0.78.

EPS history for Exelixis from 2013 to 2025

Annual EPS

Year EPS Change
2025 (TTM)C$3.30
2023C$0.8914.61%
2022C$0.78-22.97%
2021C$1.01100%
2020C$0.50-65.09%
2019C$1.44-53.91%
2018C$3.13333.96%
2017C$0.72-260.61%
2016C-$0.45-58.75%
2015C-$1.09-42.45%
2014C-$1.895.3%
2013C-$1.80

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
C$14.21 338.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
C$2.34-27.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
C$17.74 447.48%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
C$5.04 55.70%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
C$10.34 219.07%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
C$4.04 24.79%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
C$4.90 51.09%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
C-$5.00-254.20%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
C-$1.14-135.29%๐Ÿ‡บ๐Ÿ‡ธ USA